Literature DB >> 31605353

Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings.

Davide Franceschini1, Alessio Bruni2, Paolo Borghetti3, Niccolò Giaj-Levra4, Sara Ramella5, Lucio Buffoni6, Serena Badellino7, Maria Andolina2, Camilla Comin8, Emanuela Vattemi9, Michela Bezzi10, Marco Trovò11, Antonio Passaro12, Alessandra Bearz13, Rita Chiari14, Franchina Tindara15, Katia Ferrari16, Gaia Piperno17, Andrea Riccardo Filippi18, Domenico Genovesi19, Vieri Scotti20.   

Abstract

PURPOSE: To report criticisms and barriers to the "real-life" application of international guidelines and recent developments in the management of locally advanced non-small cell lung cancer (NSCLC) in Italy.
METHODS: Three 2-day courses were organized. During the first day, experts in different fields of thoracic oncology gave their lecture on diagnosis and therapy for locally advanced NSCLC. During the second day, all participants were divided into four groups to discuss on a clinical case as a multidisciplinary team (MDT). The aim was to stimulate the discussion on practical issues in the management of NSCLC patients in the real-life practice.
RESULTS: A total of 196 physicians were involved in the courses as learners. Invasive diagnosis of nodal disease for staging purposes, a priori definition of "surgical resectability" and a regular MDT with all crucial participants available were the three main key points identified for a good management of these patients. The main barriers to the clinical application of a good diagnostic and therapeutic approach to the patient were the absence of a regular and complete MDT in the South and Centre of Italy, while in the North of Italy, time for discussion of clinical cases in the MDT and waiting lists for staging and therapeutic interventions were deemed as the major concerns.
CONCLUSION: The meetings showed that diagnosis and treatment of locally advanced NSCLC are still extremely variable between different Italian regions. Logistic issues, waiting lists, paucity of well-trained staff and expertise seem to be the main barriers to international guidelines application.

Entities:  

Keywords:  Multidisciplinary evaluation; Non small cell lung cancer; Stage III

Mesh:

Year:  2019        PMID: 31605353     DOI: 10.1007/s11547-019-01094-w

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  13 in total

1.  Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.

Authors:  R Bueno; W G Richards; S J Swanson; M T Jaklitsch; J M Lukanich; S J Mentzer; D J Sugarbaker
Journal:  Ann Thorac Surg       Date:  2000-12       Impact factor: 4.330

2.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system.

Authors:  Vivien W Chen; Bernardo A Ruiz; Mei-Chin Hsieh; Xiao-Cheng Wu; Lynn A G Ries; Denise R Lewis
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

4.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

5.  Is there a role for the high-risk multidisciplinary team meeting in thoracic surgery?

Authors:  Nnamdi Nwaejike; Ehab Elbur; Ignacio Malagon; Natalie Dodman; Kath Hewitt; Eustace Fontaine; Piotr Krysiak; Mark Jones; Rajesh Shah; Kandadai S Rammohan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-01-24

Review 6.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives.

Authors:  Robert J Cerfolio; Lee Maniscalco; Ayesha S Bryant
Journal:  Ann Thorac Surg       Date:  2008-09       Impact factor: 4.330

8.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Nithya Ramnath; Thomas J Dilling; Loren J Harris; Anthony W Kim; Gaetane C Michaud; Alex A Balekian; Rebecca Diekemper; Frank C Detterbeck; Douglas A Arenberg
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 9.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer.

Authors:  Hans Wildiers; Pieter Heeren; Martine Puts; Eva Topinkova; Maryska L G Janssen-Heijnen; Martine Extermann; Claire Falandry; Andrew Artz; Etienne Brain; Giuseppe Colloca; Johan Flamaing; Theodora Karnakis; Cindy Kenis; Riccardo A Audisio; Supriya Mohile; Lazzaro Repetto; Barbara Van Leeuwen; Koen Milisen; Arti Hurria
Journal:  J Clin Oncol       Date:  2014-08-20       Impact factor: 44.544

10.  Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.

Authors:  Sung Hwan Kim; Jong Hoon Lee; Guk Jin Lee; Songmi Jeong; Yoo-Kang Kwak; Hoon-Kyo Kim; Deog Gon Cho; Young Ha Park; Mina Yu; Sei Chul Yoon
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

View more
  4 in total

Review 1.  Diffusion weighted imaging and diffusion kurtosis imaging in abdominal oncological setting: why and when.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Ginevra Danti; Eleonora Bicci; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-06-09       Impact factor: 3.698

2.  Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases.

Authors:  Ben Man Fei Cheung; Kin Sang Lau; Victor Ho Fun Lee; To Wai Leung; Feng-Ming Spring Kong; Mai Yee Luk; Kwok Keung Yuen
Journal:  Radiat Oncol J       Date:  2021-10-26

Review 3.  Lung Cancer Imaging: Screening Result and Nodule Management.

Authors:  Susanna Guerrini; Davide Del Roscio; Matteo Zanoni; Paolo Cameli; Elena Bargagli; Luca Volterrani; Maria Antonietta Mazzei; Luca Luzzi
Journal:  Int J Environ Res Public Health       Date:  2022-02-21       Impact factor: 3.390

4.  Smile InTM Totems in Radiotherapy: Patients' Satisfaction with Limited Equipment and COVID-19.

Authors:  Marzia Borgia; Fiorella Cristina Di Guglielmo; Marco Lucarelli; Rosario Bonelli; Lucrezia Gasparini; Angelo Di Pilla; Lucia Anna Ursini; Maria Taraborrelli; Annamaria Vinciguerra; Antonietta Augurio; Monica Di Tommaso; Marianna Trignani; Marianna Nuzzo; Consuelo Rosa; Giuditta Chiloiro; Stephanie Sartori; Lucia Ferrari; Roberta Marchione; Fabio Adalgiso D'Orazio; Paola Di Renzo; Giustino Orlando; Domenico Genovesi; Luciana Caravatta
Journal:  Healthcare (Basel)       Date:  2022-08-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.